Lclt. Van Kempen et al., Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin, AM J PATH, 156(3), 2000, pp. 769-774
Citations number
29
Categorie Soggetti
Research/Laboratory Medicine & Medical Tecnology","Medical Research Diagnosis & Treatment
Expression of activated leukocyte cell adhesion molecule (ALCAM)/CD166 corr
elates with the aggregation and metastatic capacity of human melanoma cell
Lines (Am J Pathol 1998, 152:805-813). Immunohistochemistry on a series of
human melanocytic lesions reveals that ALCAM expression correlates with mel
anoma progression. Most nevi (34/38) and all thin melanomas studied (Clark
levels I and II) did not express ALCAM. In contrast, immunoreactivity was d
etected in the invasive, vertical growth phase of 2 of the 13 Clark level I
II lesions tested. The fraction of positive lesions further increased in Cl
ark level IV (13/19) and in Clark level V (4/4) lesions. ALCAM expression w
as exclusively detectable in the vertical growth phase of the primary tumor
. In melanoma metastases, approximately half of the lesions tested (13/28)
mere ALCAM positive. According to the Breslow-thickness, ALCAM expression w
as observed in less than 10% of the lesions that were thinner than 1.5 mm a
nd in over 70% of the lesions that mere thicker than 1.5 mm. Our results st
rongly suggest that ALCAM plays an important role in melanocytic tumor prog
ression and depict it as a new molecular marker for neoplastic progression
of primary human melanoma.